【美国临床阶段制药公司】玛莱克琳生物技术公司Moleculin Biotech, Inc.（MBRX）美股招股说明书 S-1（首版）（英文版）（55页）.pdf

《【美国临床阶段制药公司】玛莱克琳生物技术公司Moleculin Biotech, Inc.（MBRX）美股招股说明书 S-1（首版）（英文版）（55页）.pdf》由会员分享，可在线阅读，更多相关《【美国临床阶段制药公司】玛莱克琳生物技术公司Moleculin Biotech, Inc.（MBRX）美股招股说明书 S-1（首版）（英文版）（55页）.pdf（55页珍藏版）》请在三个皮匠报告上搜索。

1、S-1 1 mbrx20250529c_s1.htm FORM S-1 Table of Contents As filed with the U.S.Securities and Exchange Commission on June 2,2025.Registration No.333-UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933 Moleculin Biotech,Inc.(E

2、xact name of registrant as specified in its charter)Delaware283447-4671997(State or other jurisdiction of(Primary Standard Industrial(I.R.S.Employerincorporation or organization)Classification Code Number)Identification Number)5300 Memorial Drive,Suite 950Houston,Texas 77007(713)300-5160(Address,inc

3、luding zip code,and telephone number,including area code,of registrants principal executive offices)Walter V.Klemp,Chief Executive Officer and Chairman5300 Memorial Drive,Suite 950Houston,Texas 77007(713)300-5160(Name,address,including zip code,and telephone number,including area code,of agent for s

4、ervice)Copies to:Cavas S.PavriJohnathan C.DuncanArentFox Schiff LLP1717 K Street NWWashington,DC 20006Telephone:(202)857-6000Fax:(202)857-6395Charles Phillips,Esq.Ellenoff Grossman&Schole LLP1345 Avenue of the Americas,11th FloorNew York,New York 10105Phone:(212)370-1300 Approximate date of commence

5、ment of proposed sale to the public:As soon as practicable after the effective dateof this Registration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant toRule 415 under the Securities Act of 1933,check the following box.If

6、this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list the Securities Act registration statement number of the earlier effective registrationstatement for the same offering.2025/6/4 11:17mbrx2025052